Full Press Release Details
Zafgen Announces Third Quarter 2015 Financial Results
Company to Host Conference Call at 4:30 PM Eastern Time to Review Progress with Beloranib Program
Ends Quarter with Cash, Cash Equivalents and Marketable Securities of $204 Million; Increases
Year-End Cash Guidance to Greater than $180 Million
BOSTON November 10, 2015 Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and
well-being of patients affected by obesity and complex metabolic disorders, today announced third quarter 2015 financial results and provided an update on the Company s clinical development programs, including the pivotal Phase 3 ZAF-311
bestPWS clinical trial of beloranib in Prader-Willi syndrome (PWS) and the Phase 2b ZAF-203 clinical trial of beloranib in severe obesity complicated by type 2 diabetes.
We are focused on advancing our understanding of the potential efficacy and safety of beloranib in complex metabolic disorders, including PWS, and
remain committed to the continued development of this promising program, said Dr. Thomas Hughes, Chief Executive Officer of Zafgen. The results from the pivotal Phase 3 ZAF-311 bestPWS and Phase 2b ZAF-203 clinical trials, together
with the insights we are gaining from our thromboembolic disease screening and monitoring measures, will be critical in determining the potential benefit-risk profile for beloranib and next steps for the program, including the design of our second
Phase 3 clinical trial for beloranib in PWS, ZAF-312.
Our newly implemented safety screening measures are progressing well as patients begin
to resume open-label treatment in our ZAF-311 bestPWS clinical trial, with a continued focus on patient safety, said Dr. Dennis Kim, Chief Medical Officer of Zafgen. Resuming open-label treatment allows us to continue to provide
beloranib as a potential treatment option to meet the urgent unmet medical need of patients with PWS, a life-threatening and complex rare disorder that severely impacts the quality of life of both patients and their families.
Third Quarter 2015 Financial Results
Our balance sheet remains strong, said Patricia Allen, Chief Financial Officer of Zafgen. With the revised beloranib development timeline and
our anticipated cash burn rate, we now expect that our cash, cash equivalents and marketable securities balance at the end of calendar year 2015 will be greater than $180 million.
Cash, Cash Equivalents and Marketable Securities
As of September 30, 2015, the Company had cash, cash equivalents and marketable securities totaling $204.0 million.
The Company reported a net loss for the
third quarter of 2015 of $19.9 million, or $0.73 per share, compared to a net loss of $14.7 million, or $0.65 per share, for the third quarter of 2014. The weighted average common shares outstanding (basic and diluted) used to compute net loss per
share were 27,138,667 for the third quarter of 2015, compared to 22,707,012 for the third quarter of 2014.
Research and Development Expenses
Research and development expenses for the third quarter of 2015 were $14.2 million, compared to $12.1 million for the third quarter of 2014. The
increase in research and development expenses for the quarter ended September 30, 2015 as compared to the quarter ended September 30, 2014 was primarily due to increased costs associated with the advancement of the Company s beloranib
program, ZGN-839 and second-generation MetAP2 inhibitors, as well as personnel related costs. Partially offsetting these results was a $6.7 million licensing fee, primarily to Chong Kun Dang Pharmaceutical Corporation (CKD Pharma) related to the
initiation of the Company s Phase 3 ZAF-311 bestPWS clinical trial, incurred in the quarter ended September 30, 2014.
Administrative Expenses
General and administrative expenses for the third quarter of 2015 were $5.5 million, compared to $2.3 million for the
third quarter of 2014. The increase in general and administrative expenses for the quarter ended September 30, 2015 as compared to the quarter ended September 30, 2014 was primarily due to increased personnel related costs, and increased
professional and consulting fees, primarily commercial-readiness activities related to PWS.
2015 Financial Guidance
The Company now expects that its cash, cash equivalents and marketable securities balance will be greater than $180.0 million at December 31, 2015.
Conference Call Information
Zafgen will host an investor conference call today, November 10, 2015 at 4:30 p.m., Eastern Time, to discuss the Company s third quarter 2015 results
as well as other forward-looking information about Zafgen s business. Investors and other interested parties may participate by dialing 844-824-7428 in the United States or 973-500-2177 outside the United States. The call will also be webcast
live on the Company s website at http://ir.zafgen.com/events.cfm. You can access the replay for seven days by dialing 855-859-2056 in the United States or 404-537-3406 outside the United States and referencing conference ID number 72381816.
Beloranib is a novel,
first-in-class injectable small molecule therapy with a unique mechanism of action that reduces hunger while stimulating the use of stored fat as an energy source. Beloranib is a potent inhibitor of methionine aminopeptidase 2, or MetAP2, an enzyme
that modulates the activity of key cellular processes that control metabolism. MetAP2 inhibitors work, at least in part, by directing MetAP2 binding to cellular stress mediators, and, thus, reducing the tone of signals that drive lipid synthesis by
the liver and fat storage throughout the body. In this manner, MetAP2 inhibition increases metabolism of fat as an energy source. Zafgen holds exclusive worldwide rights (exclusive of South Korea) for the development and commercialization of
beloranib. Zafgen exclusively licensed beloranib from Chong Kun Dang Pharmaceutical Corporation (CKD Pharma) of South Korea.
Prader-Willi syndrome (PWS), the most common known genetic cause of life-threatening obesity, results in constant and unrelenting
hunger that drives patients with PWS to engage in problematic hunger-related behaviors and to gain excessive weight. As a result, many of those affected with PWS become morbidly obese and suffer significant mortality. Currently, there is no cure for
this disease. Although the cause of PWS is complex, it results from a deletion or loss of function of a cluster of genes on the 15th chromosome. PWS typically causes low muscle mass and function, short stature, incomplete sexual development, and a
chronic feeling of hunger that, when coupled with a metabolism that utilizes drastically fewer calories than normal, can lead to excessive eating and life-threatening obesity. PWS occurs in males and females equally and in all races, with the same
incidence around the world. Prevalence estimates have ranged from 1:8,000 to 1:50,000.
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex
metabolic disorders. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms through the methionine aminopeptidase 2, or MetAP2, pathway. Beloranib, Zafgen s lead product candidate, is a novel,
first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome and obesity caused by hypothalamic injury, including
craniopharyngioma-associated obesity; and severe obesity in the general population. Zafgen is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic
steatohepatitis, or NASH, and abdominal obesity, as well as second-generation MetAP2 inhibitors. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a
team accomplished in bringing therapies to patients with both rare and prevalent metabolic diseases.
Safe Harbor Statement
Various statements in this release concerning Zafgen s future expectations, plans and prospects, including without limitation, Zafgen s expectations
regarding beloranib as a treatment for PWS, HIAO, including craniopharyngioma-associated obesity, and other forms of severe obesity, including severe obesity in patients with type 2 diabetes, its expectations with respect to the timing and success
of its clinical trials of beloranib and other product candidates, the expected requirements and timing of additional requirements for ongoing and planned clinical trials of beloranib and other product candidates, the need for additional
clinical trials and pre-clinical studies for beloranib and its other product candidates, its plans regarding commercialization of beloranib for PWS, and its anticipated cash, cash equivalents and marketable securities balance at the end of 2015 may
constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by terminology such as
anticipate, believe, could, could increase the likelihood, estimate, expect, intend, is planned, may, should, will,
will enable, would be expected, look forward, may provide, would or similar terms, variations of such terms or the negative of those terms. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various important factors, including, without limitation, Zafgen s ability to obtain a release of the partial clinical hold that the FDA placed on beloranib, the risk that the FDA may
decide to elevate the partial clinical hold on beloranib to a full clinical hold, Zafgen s ability to successfully demonstrate the efficacy and safety of beloranib and its other product candidates the risk that patients may be unwilling to
re-consent to participate in the open-label expansion portion of its ZAF-311 clinical trial or that patients may be unwilling to consent to participate in future clinical trials, the pre-clinical and clinical results for its product candidates,
which may not support further development, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting its intellectual property, Zafgen s ability to enforce its
patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, Zafgen s ability to manage operating expenses, Zafgen s ability to obtain
additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Zafgen s dependence on third parties for development, manufacture, marketing, sales and distribution of
products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled Risk Factors in Zafgen s most recent Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Zafgen s subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent
Zafgen s views only as of today and should not be relied upon as representing its views as of any subsequent date. Zafgen explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information,
future events or otherwise.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Revenue | $ | $ | $ | $ | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 14,171 | 12,076 | 36,912 | 20,046 | ||||||||||||
| General and administrative | 5,546 | 2,285 | 13,655 | 4,822 | ||||||||||||
| Total operating expenses | 19,717 | 14,361 | 50,567 | 24,868 | ||||||||||||
| Loss from operations | (19,717 | ) | (14,361 | ) | (50,567 | ) | (24,868 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 143 | 1 | 245 | 2 | ||||||||||||
| Interest expense | (200 | ) | (213 | ) | (626 | ) | (658 | ) | ||||||||
| Foreign currency transaction gains (losses), net | (110 | ) | (116 | ) | (164 | ) | (23 | ) | ||||||||
| Total other income (expense), net | (167 | ) | (328 | ) | (545 | ) | (679 | ) | ||||||||
| Net loss | (19,884 | ) | (14,689 | ) | (51,112 | ) | (25,547 | ) | ||||||||
| Accretion of redeemable convertible preferred stock to redemption value | (92 | ) | ||||||||||||||
| Net loss attributable to common stockholders | $ | (19,884 | ) | $ | (14,689 | ) | $ | (51,112 | ) | $ | (25,639 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.73 | ) | $ | (0.65 | ) | $ | (1.92 | ) | $ | (2.97 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 27,138,667 | 22,707,012 | 26,593,646 | 8,618,793 |
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| September 30, 2015 | December 31, 2014 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 38,763 | $ | 58,103 | ||||
| Marketable securities | 165,191 | 57,359 | ||||||
| Tax incentive receivable | 334 | 391 | ||||||
| Prepaid expenses and other current assets | 1,802 | 1,345 | ||||||
| Total current assets | 206,090 | 117,198 | ||||||
| Property and equipment, net | 303 | 79 | ||||||
| Tax incentive receivable | 975 | |||||||
| Other assets | 79 | 242 | ||||||
| Total assets | $ | 207,447 | $ | 117,519 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,151 | $ | 2,348 | ||||
| Accrued expenses | 6,556 | 3,172 | ||||||
| Notes payable, current | 2,877 | 1,381 | ||||||
| Total current liabilities | 13,584 | 6,901 | ||||||
| Notes payable, net of discount, long-term | 4,162 | 6,177 | ||||||
| Total liabilities | 17,746 | 13,078 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Preferred stock; $0.001 par value; 5,000,000 shares authorized at September 30, 2015 and December 31, 2014; no shares issued and outstanding at September 30, 2015 and December 31, 2014 | ||||||||
| Common stock, $0.001 par value; 115,000,000 shares authorized at September 30, 2015 and December 31, 2014; 27,233,574 and 22,879,160 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively | 27 | 23 | ||||||
| Additional paid-in capital | 346,203 | 209,838 | ||||||
| Accumulated deficit | (156,497 | ) | (105,385 | ) | ||||
| Accumulated other comprehensive loss | (32 | ) | (35 | ) | ||||
| Total stockholders' equity | 189,701 | 104,441 | ||||||
| Total liabilities and stockholders' equity | $ | 207,447 | $ | 117,519 |
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto
included in the Company s Annual Report on Form 10-K which includes the audited consolidated financial statements for the year ended December 31, 2014.
Chief Financial Officer